

<b>CV Date</b>	18/03/2022
----------------	------------

### Part A. PERSONAL INFORMATION

First Name *	Sara		
Family Name *	Lopez-Tarruella Cobo		
Sex *	Female	Date of Birth *	
ID number Social Security, Passport *		Phone Number *	
URL Web			
Email Address			
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0002-2606-9538	
	Researcher ID		
	Scopus Author ID		

\* Mandatory

#### A.1. Current position

Job Title	Physician Assistant (Medical Oncology)		
Starting date	2010		
Institution	Hospital General Universitario Gregorio Marañón		
Department / Centre	MEDICAL ONCOLOGY / MEDICAL ONCOLOGY SERVICE		
Country		Phone Number	
Keywords			

#### A.2. Previous positions

Period	Job Title / Name of Employer / Country
2016 - 2022	Associate Professor / Universidad Complutense de Madrid
2008 - 2010	Physician Assistant (Medical Oncology) / Hospital Clínico San Carlos
2007 - 2008	Physician Assistant (Medical Oncology) / Hospital Universitario Marqués de Valdecilla
2002 - 2006	Medical Oncology Resident (MIR) / Hospital Clínico San Carlos

#### A.3. Education

Degree/Master/PhD	University / Country	Year
PhD Degree, Medicine Department	Universidad Complutense de Madrid	2009
RESEARCH FELLOWSHIP	BREAST CENTER AT BAYLOR COLLEGE OF MEDICINE (HOUSTON, TX)	2007
DEGREE IN MEDICINE AND SURGERY	Universidad Autónoma de Madrid	2001

#### A.4. General quality indicators of scientific production

o REPORT OF QUOTES (source Web of Science, Principal Collection of Web of Science)  
 Results found: 86 Total of times cited: 839 Total of times quoted without own quotes: 824  
 Articles that cited: 817 Total of articles that cited without own quotes: 803 Average citations per item: 9.76 h-index: 18

### Part B. CV SUMMARY

I got my MD degree at Universidad Autónoma (Madrid, 2001) and after completing my residency program at Hospital Clínico San Carlos (Universidad Complutense, Madrid) I obtained board certification in Medical Oncology (2006). After specializing, I began my

postdoctoral fellowship in basic/translational research at Baylor College of Medicine in the Breast Center (Houston), under the direction of Dr. CK. Osborne and Dr. R Schiff. Our research was focused on understanding the key signaling pathways in breast cancer and on identifying therapeutic strategies to overcome them, particularly treatments targeting the estrogen receptor and the HER2 receptor. Back in Spain, I obtained my Ph.D. degree at Universidad Complutense (Madrid) studying de novo metastatic breast cancer prognostic factors in the GEICAM Alamo project I-II (2009). From 2007, I have had three consecutive appointments at university hospitals in the country and I am currently working as an attending physician at Gregorio Marañón General Hospital, HGUGM, (Madrid).

I have a deep compromise with teaching by participating in conferences, seminars and developing a mentor role of undergraduate and postgraduate students at HGUGM. Since November 2016, I have an appointment of Assistant Professor of Medicine at Complutense University (Madrid). At the hospital level, since 2013, I collaborate in the training of medical oncology residents as part of the resident tutorship team as well.

As a member of the breast cancer unit in the Oncology Department of HGUGM, I am PI or co-investigator of several clinical and translational research trials. Another aspect of my clinical research interest is the development of early phase clinical trials, participating as an active member of the first-in-human phase I team at the Department. The direct connection with the translational oncology research lab is one of the main aims of my daily practice, with a primary focus on the development of in vitro and in vivo preclinical models (PDX) in breast cancer.

I am full member of national and international scientific societies (SEOM, ESMO...), in the context of SEOM, as cancer physician, I am elected member of the Board of Directors (2021-23). As clinical-translational researcher, I participate in the Spanish Breast Cancer Group (GEICAM), beginning with the development of my thesis project in 2004 until today I have been directly involved in the Alamo and RegistEM RWE Registries, and I have also participated in the elaboration of the GEICAM guidelines either for the management of metastatic breast cancer or, more recently, for the management of breast cancer during the COVID-19 pandemic.

#### **Organization of R&D activities**

- National Scientific Society (SEOM): Board of Directors member. Coordinator of SEOM clinical guidelines in advanced breast and recurrent breast cancer (2018). Organizing committee member of the 2022 SEOM Congress.
- Independent Research Cooperative Group (GEICAM): TNBC working group member (2015) and coordinator (2018-). Board of Directors member & Scientific Committee member (2018-).
- Stable structures for collaborative research in Health Sciences: Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). Group member of CB16/12/00471 (from 2016). Topic: Development of new targeted and immune therapies for luminal, HER2-positive and /or triple negative breast cancer therapies, Principal investigator: Miguel Marfín Jiménez. Member of Liquid Biopsy (LB) Work Module at CIBERONC, formed by researchers from different programs to establish a platform for the standardization and promotion of the LB within the CIBERONC network.
- Regional Healthcare System: SERMAS. Member of the Working Group for the Review of Criteria of the Oral Antineoplastics Use (2016-) from the Pharmaceutical & Medical Products Section. Madrid Oncologic Network (ROM). Member of the Breast Cancer Working Group team (2022-).

## **Part C. RELEVANT ACCOMPLISHMENTS**

### **C.1. Publications**

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Yau, Christina; Osdoit, Marie; van der Noordaa, Marieke; et al; Lopez-Tarruella, Sara; Symmans, W Fraser. (16/48). 2022. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. *The Lancet. Oncology.* 23-1, pp.149-160. ISSN 1474-5488. WOS (0) [https://doi.org/10.1016/S1470-2045\(21\)00589-1](https://doi.org/10.1016/S1470-2045(21)00589-1)
- 2 **Scientific paper.** Bueno Muino, Coralia; Martin, Miguel; del Monte-Millan, Maria; Garcia-Saenz, Jose angel; Lopez-Tarruella, Sara (AC). (5/5). 2022. HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping *CANCERS.* 14. <https://doi.org/10.3390/cancers14030512>
- 3 **Scientific paper.** Lopez-Tarruella, Sara; Echavarria, Isabel; Jerez, Yolanda; Herrero, Blanca; Gamez, Salvador; Martin, Miguel. (1/6). 2022. How we treat HR-positive, HER2-negative early breast cancer *FUTURE ONCOLOGY.* ISSN 1479-6694. <https://doi.org/10.2217/fon-2021-0668>
- 4 **Scientific paper.** Villalvazo, Priscila; Marzal-Alfaro, Belen; Garcia-Alfonso, Pilar; et al; Lopez-Tarruella, Sara; Lopez-Fernandez, Luis Andres. (6/15). 2021. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. *Journal of personalized medicine.* 11-8. ISSN 2075-4426. WOS (0) <https://doi.org/10.3390/jpm11080792>
- 5 **Scientific paper.** (5/9). 2021. Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer <https://doi.org/10.3390/math9030222>
- 6 **Scientific paper.** Martin, Miguel; Ramos-Medina, Rocio; Bernat, Rebeca; et al; Lopez-Tarruella, Sara. (23/23). 2021. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts *SCIENTIFIC REPORTS.* 11. ISSN 2045-2322. WOS (3) <https://doi.org/10.1038/s41598-021-85962-4>
- 7 **Scientific paper.** Marquez-Rodas, Ivan; Longo, Federico; Rodriguez-Ruiz, Maria E.; et al; Lopez-Tarruella, Sara; Melero, Ignacio. (10/27). 2020. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors *SCIENCE TRANSLATIONAL MEDICINE. AMER ASSOC ADVANCEMENT SCIENCE.* 12-565. ISSN 1946-6234. WOS (3) <https://doi.org/10.1126/scitranslmed.abb0391>
- 8 **Scientific paper.** Perez Ramirez, S.; del Monte-Millan, M.; Lopez-Tarruella, S.; et al; Martin, M.(3/24). 2020. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience *CLINICAL & TRANSLATIONAL ONCOLOGY. SPRINGER INTERNATIONAL PUBLISHING AG.* 22-5, pp.717-724. ISSN 1699-3055. WOS (0) <https://doi.org/10.1007/s12094-019-02176-x>
- 9 **Scientific paper.** Yolanda Jerez; Ivan Márquez-Rodas; Inmacula Aparico; Manuel Alva; Miguel Martin; Sara López-Tarruella. (6/6). 2020. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations *DRUGS.* <https://doi.org/10.1007/s40265-019-01235-5>
- 10 **Scientific paper.** Lopez-Tarruella, Sara; Escudero, M. J.; Pollan, Marina; et al; Carrasco, E.(1/21). 2019. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/EI Alamo Registry) *SCIENTIFIC REPORTS. NATURE PUBLISHING GROUP.* 9. ISSN 2045-2322. WOS (0) <https://doi.org/10.1038/s41598-019-55765-9>
- 11 **Scientific paper.** Picornell, A. C.; Echavarria, I.; Alvarez, E.; et al; Lopez-Tarruella, S.; Martin, M.(4/20). 2019. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series *BMC GENOMICS. BMC.* 20. ISSN 1471-2164. WOS (1) <https://doi.org/10.1186/s12864-019-5849-0>
- 12 **Scientific paper.** Moreno, Fernando; Gayarre, Javier; Lopez-Tarruella, Sara; et al; Martin, Miguel. (3/23). 2019. Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study *JCO PRECISION ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.* 3. ISSN 2473-4284. WOS (0) <https://doi.org/10.1200/PO.18.00263>

- 13 **Scientific paper.** Sharma, Priyanka; Lopez-Tarruella, Sara; Angel Garcia-Saenz, Jose; et al; Martin, Miguel. (2/33). 2018. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. 24-23, pp.5820-5829. ISSN 1078-0432. WOS (8) <https://doi.org/10.1158/1078-0432.CCR-18-0585>
- 14 **Scientific paper.** Martin, M.; de la Torre-Montero, J. C.; Lopez-Tarruella, S.; et al; Lluch, A.(3/16). 2018. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling BREAST CANCER RESEARCH AND TREATMENT. SPRINGER. 171-3, pp.627-634. ISSN 1573-7217. WOS (10) <https://doi.org/10.1007/s10549-018-4855-2>
- 15 **Scientific paper.** Lobo, Miriam; Lopez-Tarruella, Sara; Luque, Soledad; et al; Marquez-Rodas, Ivan. (2/15). 2018. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit JOURNAL OF GENETIC COUNSELING. WILEY. 27-4, pp.854-862. ISSN 1059-7700. WOS (3) <https://doi.org/10.1007/s10897-017-0187-3>
- 16 **Scientific paper.** Pernas, Sonia; Martin, Miguel; Kaufman, Peter A.; et al; Lopez-Tarruella, Sara; Cortes, Javier. (6/22). 2018. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 19-6, pp.812-824. ISSN 1470-2045. WOS (23) [https://doi.org/10.1016/s1470-2045\(18\)30147-5](https://doi.org/10.1016/s1470-2045(18)30147-5)
- 17 **Scientific paper.** Echavarria, Isabel; Lopez-Tarruella, Sara; Picornell, Antoni; et al; Martin, Miguel. (2/22). 2018. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. 24-8, pp.1845-1852. ISSN 1078-0432. WOS (11) <https://doi.org/10.1158/1078-0432.CCR-17-1912>
- 18 **Scientific paper.** Garcia-Gonzalez, Xandra; Lopez-Tarruella, Sara; Isabel Garcia, Maria; et al; Andres Lopez-Fernandez, Luis. (2/12). 2018. Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene CANCER MANAGEMENT AND RESEARCH. DOVE MEDICAL PRESS LTD. 10, pp.4517-4522. ISSN 1179-1322. WOS (0) <https://doi.org/10.2147/CMAR.S174470>
- 19 **Scientific paper.** Marquez-Rodas, Ivan; Pollan, Marina; Jose Escudero, Maria; et al; Lopez-Tarruella, Sara. (23/23). 2017. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "EIA Alamo III" retrospective study PLOS ONE. PUBLIC LIBRARY SCIENCE. 12-10. ISSN 1932-6203. WOS (0) <https://doi.org/10.1371/journal.pone.0184181>
- 20 **Scientific paper.** Lopez-Tarruella, Sara; Jerez, Yolanda; Marquez-Rodas, Ivan; Echavarria, Isabel; Martin, Miguel. (1/5). 2017. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer FUTURE ONCOLOGY. FUTURE MEDICINE LTD. 13-24, pp.2137-2149. ISSN 1744-8301. WOS (5) <https://doi.org/10.2217/fo-2017-0183>
- 21 **Scientific paper.** Echavarria, Isabel; Jerez, Yolanda; Martin, Miguel; López-Tarruella, Sara. (4/4). 2017. Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care (Basel, Switzerland). 12-5, pp.296-302. ISSN 1661-3791.
- 22 **Scientific paper.** Sharma, Priyanka; Lopez-Tarruella, Sara; Angel Garcia-Saenz, Jose; et al; Martin, Miguel. (2/34). 2017. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. 23-3, pp.649-657. ISSN 1078-0432. WOS (37) <https://doi.org/10.1158/1078-0432.CCR-16-0162>
- 23 **Scientific paper.** Echavarria, Isabel; Granja, Monica; Bueno, Coralia; et al; Lopez-Tarruella, Sara; Angel Garcia-Saenz, Jose. (4/14). 2017. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer BREAST CANCER RESEARCH AND TREATMENT. SPRINGER. 162-1, pp.181-189. ISSN 1573-7217. WOS (5) <https://doi.org/10.1007/s10549-016-4098-z>



- 24 Scientific paper.** Echavarría, Isabel; Lopez-Tarruella, Sara; Marquez-Rodas, Ivan; Jerez, Yolanda; Martín, Miguel. (2/5). 2017. Neratinib for the treatment of HER2-positive early stage breast cancer EXPERT REVIEW OF ANTICANCER THERAPY. TAYLOR & FRANCIS LTD. 17-8, pp.669-679. ISSN 1744-8328. WOS (11) <https://doi.org/10.1080/14737140.2017.1338954>
- 25 Scientific paper.** Márquez-Rodas, I.; Lobo, M.; Flores-Sanchez, C.; et al; López-Tarruella, S.; Martín, M.(13/20). 2017. Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital.Oncology. 92-2, pp.68-74. ISSN 1423-0232. <https://doi.org/10.1159/000452280>
- 26 Guideline.** Martín, Miguel; Guerrero-Zotano, Angel; Montero, Angel; et al; Lopez Tarruella, Sara; GEICAM Spanish Breast Canc Grp Ste. (16/16). 2020. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain ONCOLOGIST. WILEY. 25-9, pp.E1339-E1345. ISSN 1083-7159. WOS (1) <https://doi.org/10.1634/theoncologist.2020-0363>
- 27 Guideline.** Chacón López-Muñiz, J. I.; de la Cruz Merino, L.; Gavilá Gregori, J.; et al; López-Tarruella Cobo, S.(10/10). 2019. {SEOM} clinical guidelines in advanced and recurrent breast cancer (2018) Clinical and Translational Oncology. 21-1, pp.31-45. ISSN 1699-3055. <https://doi.org/10.1007/s12094-018-02010-w>
- 28 opinion article.** Calin, Ana; Martín, Miguel; Lopez-Tarruella, Sara. (3/3). 2018. Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations ANNALS OF TRANSLATIONAL MEDICINE. 6. ISSN 2305-5847. WOS (0) <https://doi.org/10.21037/atm.2018.10.68>

## C.2. Conferences and meetings

- 1** Kaufman, Peter A.; Pernas Simon, Sonia; Martín, Miguel; Gil-Martín, Marta; Gómez Pardo, Patricia; Lopez-Tarruella, Sara; Manso, Luis; Ciruelos, Eva; Alejandro Pérez-Fidalgo, José; Hernando, Cristina; Ademuyiwa, Foluso Olabisi; Weilbaeher, Katherine N.; Mayer, Ingrid A.; Pluard, Timothy J.; Martínez García, María; Vahdat, Linda T.; Barker, Debra; Romagnoli, Barbara; Cortes, Javier. Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Amer Soc Clin Oncol.
- 2** Cortes Castan, J.; Martín, M.; Pernas Simon, S.; Gómez Pardo, P.; Lopez-Tarruella, S.; Gil Martín, M.; Manso, L. M.; Ciruelos, E. M.; Pérez Fidalgo, J. A.; Hernando, C.; Ademuyiwa, F.; Weilbaeher, K.; Mayer, I. A.; Pluard, T.; García, M. Martínez; Vahdat, L. T.; Wach, A.; Barker, D.; Romagnoli, B.; Kaufman, P. A.. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. 43rd ESMO Congress (ESMO). European Soc Med Oncol; Japanese Soc Med Oncol.
- 3** Alvarez, Isabel; Guerrero, Angel; Lopez-Tarruella, Sara; Martínez, Purificación; Mori, Marta; Faló, Catalina; Antolín, Silvia; Rodríguez, César A.; Margeli, Mireia; Garau, Isabel; Tibau, Ariadna; Moreno, Diana; Cruz, Josefina; José Echarri, María; Anton, Antonio; Rodríguez-Lescure, Álvaro; José Escudero, María; Bezares, Susana; Rojo, Federico; Jara, Carlos. Characteristics of HR+/HER2-patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM). 2021 San Antonio breast Cancer Symposium.
- 4** Alvarez, Isabel; Guerrero-Zotano, Angel; Lopez-Tarruella, Sara; Martínez, Purificación; Mori, Marta; Faló, Catalina; Antolín, Silvia; Rodríguez, César A.; Margeli, Mireia; Garau, Isabel; Tibau, Ariadna; Moreno, Diana; Cruz, Josefina; Echarri, M. José; Lao, Juan; Rodríguez-Lescure, Álvaro; José Miralles, Juan; Bezares, Susana; Rojo, Federico; Jara, Carlos. Characteristics of HR+/HER2-patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM). 2021 San Antonio breast Cancer Symposium.

- 5 Perez Ramirez, S.; del Monte-Millan, M.; Lopez-Tarruella, S.; Marquez-Rodas, I.; Jerez, Y.; Lobo Samper, F.; Izarzugaza Peron, Y.; Martinez Janez, N.; Garcia-Saenz, J. A.; Moreno Anton, F.; Zamora Aunon, P.; Arroyo Yustos, M.; Lara Alvarez, M. A.; Ciruelos Gil, E. M.; Manso Sanchez, L.; Echarri Gonzalez, M. J.; Guerra Martinez, J. A.; Jara Sanchez, C.; Valentin Maganto, V.; Martin Jimenez, M.. Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by immunohistochemistry: A retrospective study in Spanish population. 42nd European-Society-for-Medical-Oncology Congress (ESMO). European Soc Med Oncol.
- 6 Lobo, M.; Lopez-Tarruella, S.; Luque, S.; Lizarraga, S.; Rincon, P.; Hernandez, A.; Mendizabal, E.; Bueno, O.; Cebollero, M.; Perez Ramirez, S.; Jerez, Y.; Palomero Plaza, M. I.; Gonzalez Del Val, R.; Garcia, G.; Echavarria Diaz-Guardamino, I.; Calin, A.; Blanco, J. A.; Flores Sanchez, C.; Martin, M.; Marquez-Rodas, I.. Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation.
- 7 Jara, Carlos; Alvarez, Isabel; Margeli Vila, Mireia; Augusto Rodriguez, Cesar; Martinez, Purificacion; Norberto Batista, J.; Alonso Romero, Jose Luis; Antolin Novoa, Silvia; Ruiz, Sofia; Guerrero, Angel; Tusquets, Ignasi; Anton, Antonio; Ignacio Chacon, Jose; Rodriguez-Lescure, Alvaro; Tibau Martorell, Ariadna; Varela Ferreiro, Silvia; Jose Miralles, Juan; Bezares, Susana; Rojo, Federico; Lopez-Tarruella, Sara. First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM).. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Amer Soc Clin Oncol.
- 8 Rodas, Ivan Marquez; -Ruiz, Maria E. Rodriguez; Lopez-Tarruella, Sara; Perez-Gracia, Jose Luis; De Miguel, Enrique; Calvo, Aitana; Blanco-Codesido, Montserrat; Martin-Algarra, Salvador; Martin, Miguel; Melero, Ignacio. First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA).. 53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Amer Soc Clin Oncol.
- 9 Jara, Carlos; Rodriguez, Cesar A.; Alvarez, Isabel; Falo, Catalina; Martinez, Purificacion; Andres, Raquel; Cruz, Josefina; Mori, Marta; Adrover, Encarna; Tibau, Ariadna; Antolin, Silvia; Margeli, Mireia; Alonso, Jose L.; Pajares, Bella I.; Carmen Camara, M.; Jose Miralles, J.; Bezares, Susana; Rojo, Federico; Lopez-Tarruella, Sara; Guerrero-Zotano, Angel. Geicam/2014-03 (RegisTEM): A prospective registry of unresectable locally advanced or metastatic breast cancer: Characteristics of a subset of patients with triple negative subtype. 2021 San Antonio breast Cancer Symposium.
- 10 Jara, Carlos; Alvarez, Isabel; Rodriguez, Cesar A.; Martinez, Purificacion; Andres, Raquel; Rodriguez-Lescure, Alvaro; Malon, Diego; Luis Alonso, Jose; Adrover, Encarna; Jose Echarri, Maria; Margeli, Mireia; Tibau, Ariadna; Ramirez, Judith; Antolin, Silvia; Campo, Ruth; Jose Miralles, Juan; Bezares, Susana; Rojo, Federico; Lopez-Tarruella, Sara; Guerrero-Zotano, Angel. Geicam/2014-03 (registem): A prospective registry of advanced breast cancer: A subset of triple negative breast cancer patients with her2 low expression. 2021 San Antonio breast Cancer Symposium.
- 11 Marquez Rodas, I.; Longo, F.; Rodriguez-Ruiz, M.; Calles, A.; Perez-Gracia, J. L.; Gomez-Rueda, A.; Lopez-Tarruella, S.; Ponz-Sarvisé, M.; Alvarez, R. M.; Soria, A.; de-Miguel, E.; Gayarre, J.; Aznar, M. A.; Calvo, A.; Lopez-Casas, P. P.; Tersago, D.; Quintero, M.; Martin-Algarra, S.; Martin, M.; Melero, I.. Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. 43rd ESMO Congress (ESMO). European Soc Med Oncol; Japanese Soc Med Oncol.
- 12 Echavarria Diaz-Guardamino, I.; Lopez-Tarruella, S.; Garcia-Saenz, J. A.; Gomez Moreno, H.; Moreno, F.; Jerez, Y.; Fuentes, H.; Marquez-Rodas, I.; Cebollero, M.; Del Monte-Millan, M.; Picornell, A.; Massarrah, T.; Barnadas, A.; Prat, A.; Ballesteros Garcia, A.; Colomer Bosch, R.; Pelaez, B.; Gonzalez-Rivera, M.; Perou, C. M.; Martin, M.. Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC). 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO). European Soc Med Oncol.

- 13 Guerrero-Zotano, Angel; Jara, Carlos; Lopez-Tarruella, Sara; Rodriguez, Cesar A.; Adrover, Encarna; Faló, Catalina; Martinez, Purificacion; Antolin, Silvia; Margeli, Mireia; Cruz, Josefina; Rodriguez-Lescure, Alvaro; Iranzo, Vega; Gomez-Raposo, Cesar; Juan Illarramendi, Jose; Malon, Diego; Luis Alonso, Jose; Anton, Antonio; Andres, Raquel; Herranz, Jesus; Bezares, Susana; Caballero, Rosalia; Alvarez, Isabel; Rojo, Federico. Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM). 2021 San Antonio breast Cancer Symposium.
- 14 Diaz-Guardamino, I. Echavarria; Picornell, A. C.; Lopez-Tarruella, S.; Jerez, Y.; Hoadley, K.; Alvarez, E.; del Monte-Millan, M.; Gayarre, J.; Ramos-Medina, R.; Massarrah, T.; Ocana, I.; Cebollero, M.; Moreno Anton, F.; Garcia-Saenz, J. A.; Gomez Moreno, H.; Fuentes, H.; Ballesteros Garcia, A. I.; Bohn Sarmiento, U.; Perou, C.; Martin Jimenez, M.. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification (TNBCtype-4). 42nd European-Society-for-Medical-Oncology Congress (ESMO). European Soc Med Oncol.
- 15 Gil-Martin, Marta; Pardo, Patricia Gomez; Lopez-Tarruella, Sara; Manso, Luis; Perez-Fidalgo, Jose Alejandro; Ademuyiwa, Foluso Olabisi; Mayer, Ingrid A.; Pluard, Timothy J.; Garcia, Maria Martinez; Kaufman, Peter A.; Vandat, Linda T.; Hooftman, Leon W.; Romagnoli, Barbara; Hernando, Cristina; Weilbaecher, Katherine N.; Ciruelos, Eva M.; Martin, Miguel; Simon, Sonia Pernas; Cortes, Javier. Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET. Amer Soc Clin Oncol.
- 16 Lopez-Tarruella, Sara; del Monte-Millan, Maria; Alvarez, Enrique; Jerez, Yolanda; Garcia Saenz, Jose Angel; Echavarria, Isabel; Moreno, Fernando; Marquez-Rodas, Ivan; Bueno-Muino, Coralia; Herrero, Blanca; Cebollero, Maria; Ramos-Medina, Rocio; Lobato, Nerea; Gonzalez del Val, Ricardo; Isabel Palomero, Maria; Lizarraga, Santiago; Bohn, Uriel; Isabel Ballesteros, Ana; Rincon, Patricia; Massarrah, Tatiana; Ocana, Inmaculada; Villarejo, Lucia; Perou, Charles M.; Martin, Miguel. Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC). 2021 San Antonio breast Cancer Symposium.
- 17 Shad, Sonal; van der Noordaa, Marieke; Osdoit, Marie; de Croze, Diane; Hamy, Anne-Sophie; Lae, Marick; Reyat, Fabien; Martin, Miguel; Del Monte-Millan, Maria; Lopez-Tarruella, Sara; Boughey, Judy C.; Goetz, Matthew P.; Hoskin, Tanya; Gould, Rebekah; Valero, Vicente; Sonke, Gabe; Steenbruggen, Tessa G.; van Seijen, Maartje; Wesseling, Jelle; Bartlett, John; Edge, Stephen; Kim, Mi-Ok; Abraham, Jean; Caldas, Carlos; Earl, Helena; Provenzano, Elena; Sammut, Stephen-John; Cameron, David; Graham, Ashley; Hall, Peter; Mackintosh, Lorna; Fang, Fan; Godwin, Andrew K.; Schwensen, Kelsey; Sharma, Priyanka; DeMichele, Angela; Dunn, Janet; Hiller, Louise; Hayward, Larry; Thomas, Jeremy; Cole, Kimberly; Puztai, Lajos; Van't Veer, Laura; Symmans, Fraser; Esserman, Laura; Yau, Christina; I-SPY 2 TRIAL Consortium. Site of recurrence after neoadjuvant therapy: A multi-center pooled analysis. 2021 San Antonio breast Cancer Symposium.
- 18 Rojo Todo, F.; Stradella, A.; Garcia-Saenz, J. A.; Bermejo De Las Heras, B.; Alfonso Romero, J. L.; Barnadas, A.; Izarzugaza Peron, Y.; Alba, E.; Lopez-Tarruella, S.; Henao-Carrasco, F.; Carrasco, E.; Caballero, R.; Del Campo, M.. Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study. ESMO Virtual Congress. European Soc Med Oncol.

### C.3. Research projects and contracts

- 1 **Project.** FAITH: A Federated Artificial Intelligence solution for monitoring mental Health status after cancer treatment. H2020 European Union. McManus Gary (coordinator). (Hospital General Universitario Gregorio Marañón). 2020-2025. 400.000 €. Principal investigator.

- 2 Project.** Predictive value of the mutational load in tumor, plasma and circulating tumor cells on the response to neoadjuvant docetaxel and carboplatin combination in triple negative breast cancer patients (PI18/01775). Instituto de Salud Carlos III. (Hospital General Universitario Gregorio Marañón). 2018-2020. 196.020 €. Team member.
- 3 Project.** PROSIGNA TEST AS ROUTINE CLINICAL PRACTICE IN DIFFERENT SUBTYPES OF BREAST CANCER DIAGNOSTIC. Celgene and Universidad de Alcalá de Henares Type of entity: UniversityCity funding entity: SpainStart-. Miguel Martín Jimenez. (Hospital General Universitario Gregorio Marañón). 2017-2017. 6.000 €. Team member.
- 4 Project.** Pilot study to find out the interest, adherence and difficulties of patients diagnosed with RH positive and HER2 negative breast cancer in their participation in physical exercise programs after surgery. SARA LOPEZ-TARRUELLA COBO. (Hospital General Universitario Gregorio Marañón). From 2017.
- 5 Contract.** Identification of drug synergisms and mechanisms of drug resistance in preclinical models derived from her2-positive human breast cancer tumors PUMA Biotech. 2018-01/01/2023. 268.323 €.